Genetic Toxicology Testing Market Report 2026

The genetic toxicology testing market size has grown rapidly in recent years. It will grow from $1.8 billion in 2025 to $1.98 billion in 2026 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to regulatory safety requirements, growth of pharmaceutical r&d, early adoption of in vivo testing, industrial chemical monitoring, environmental health studies.

The genetic toxicology testing market size is expected to see strong growth in the next few years. It will grow to $2.74 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to shift toward alternative testing methods, stricter regulatory frameworks, growth in biologics development, demand for safer chemicals, expansion of toxicogenomics. Major trends in the forecast period include increased use of genotoxicity testing in drug development, growing adoption of in vitro genetic toxicology assays, rising regulatory focus on chemical safety testing, expansion of environmental genotoxicity assessment, increased demand from pharmaceutical safety studies.

The rising demand for personalized medicine is expected to fuel the growth of the genetic toxicology testing market in the coming years. Personalized medicine is an approach to healthcare that customizes medical decisions, treatments, and interventions based on an individual patient’s predicted disease risk or therapeutic response. The personalized medicine market has gained strong momentum due to advances in genetics, deeper understanding of disease mechanisms, the availability of biomarker-based diagnostic tools, value-based healthcare initiatives, and increased integration into clinical practice and research. Genetic toxicology testing supports personalized medicine by delivering critical insights into genetic variability, individual susceptibility to genotoxic agents, and potential treatment responses. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023 the FDA approved 16 new personalized medicines for patients with rare diseases, up from six approvals in 2022. As a result, the growing emphasis on personalized medicine is driving expansion of the genetic toxicology testing market.

Leading companies in the genetic toxicology testing market are concentrating on the development of innovative drug screening platforms, such as high-throughput transcriptomics, to enhance accuracy and efficiency in detecting potential genetic toxins. High-throughput transcriptomics is a technology-driven method that enables large-scale analysis of gene expression across numerous samples simultaneously, commonly using techniques such as RNA sequencing (RNA-seq). This approach allows researchers to evaluate how drugs or chemical compounds influence global cellular gene expression in a high-throughput setting, supporting the prediction of toxicological effects, mechanisms of action, and potential genotoxicity. For instance, in September 2024, Toxys, a Netherlands-based biotechnology company specializing in in vitro toxicology solutions, introduced MutaTracker, a mammalian cell-based mutagenicity and genotoxicity assay that combines its established ToxTracker reporter system with error-corrected single-molecule mutation sequencing (SMM-seq). The platform enables ultra-sensitive identification of point mutations, as rare as one in 10⁷ bases, and delivers detailed insights into genotoxic modes of action, thereby improving accuracy and reducing false-positive results compared to conventional cytogenetic assays.

In September 2024, Scantox Group, a Denmark-based contract research organization, completed the acquisition of Gentronix for an undisclosed amount. Through this acquisition, Scantox aims to strengthen and expand its service portfolio by integrating Gentronix’s specialized expertise in genetic toxicology testing. Gentronix Ltd. is a UK-based company recognized for providing precise and reliable genetic toxicology testing services.

Major companies operating in the genetic toxicology testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Laboratory Corporation of America Holdings, Eurofins Scientific SE, SGS SA, WuXi AppTec, Intertek Group plc, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Fraunhofer ITEM, Jubilant Life Sciences Limited, Evotec SE, Inotiv Inc., Promega Corporation, Syngene International Limited, Nelson Laboratories LLC, Instem, Frontage Laboratories Inc., Creative Bioarray, Creative Biolabs Inc., Gentronix Limited, MB Research Laboratories.

North America was the largest region in the genetic toxicology testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genetic toxicology testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genetic toxicology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the genetic toxicology testing market by increasing costs of imported reagents, laboratory instruments, and assay kits. Pharmaceutical and chemical safety testing laboratories are most affected due to dependence on imported consumables. These tariffs raise testing costs by increasing expenses for genotoxicity screening, regulatory compliance testing, and assay validation, potentially extending study timelines. However, they encourage local reagent manufacturing, supporting regional production of assay materials and improving long-term supply stability.

The genetic toxicology testing market research report is one of a series of new reports that provides genetic toxicology testing market statistics, including genetic toxicology testing industry global market size, regional shares, competitors with a genetic toxicology testing market share, detailed genetic toxicology testing market segments, market trends and opportunities, and any further data you may need to thrive in the genetic toxicology testing industry. This genetic toxicology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Genetic toxicology testing is a specialized area of toxicology that concentrates on evaluating the ability of chemical substances to cause damage to genetic material, including DNA, RNA, or chromosomes. The aim of genetic toxicology testing is to assess the genotoxic potential of compounds and identify any harmful effects they may exert on the genetic material of living organisms, including humans. It also serves as an essential tool for assessing the safety of pharmaceuticals, chemicals, and environmental contaminants with respect to genotoxic risks.

The primary types within the genetic toxicology testing market include in vitro and in vivo methods. In vitro refers to experiments or studies performed in a controlled laboratory setting, such as test tubes, petri dishes, or other artificial environments, outside a living organism. The different products encompass services, reagents and consumables, and assays, which are utilized across various applications including the healthcare industry, food industry, cosmetics industry, agriculture industry, and other sectors.

The genetic toxicology testing market includes revenues earned by entities through mutagenicity testing, genotoxicity screening, carcinogenicity testing, regulatory compliance, risk assessment, bacterial mutation assays, comet assays, micronucleus tests, presymptomatic testing, ancestry testing, and nutrigenomics testing, and related cell culture systems, assay kits, microscopes, flow cytometers, automation and robotics, and flow cytometry. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.